Leprosy drug holds promise as at-home treatment for COVID-19

A Nature study authored by scientists at Sanford Burnham Prebys Medical Discovery Institute and the University of Hong Kong shows that the leprosy drug clofazimine, which is FDA approved and on the World Health Organization's List of Essential Medicines, exhibits potent antiviral activities against SARS-CoV-2 and prevents the exaggerated inflammatory response associated with severe COVID-19.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news